Risk of cytomegalovirus reactivation in patients with immune-mediated inflammatory diseases undergoing biologic treatment: a real matter?
n INTRODUCTION I n rheumatic diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) and in other immune-mediated inflammatory diseases (IMID), such as chronic inflammatory bowel diseases (IBD) or multiple sclerosis (MS), biological treatments have been largely employed. Their use has resulted in an increased risk of new infectious events and reactivation of chronic/latent infectious diseases. In other immunosuppression conditions (solid organ transplant, Acquired Immune Deficiency Syndrome-AIDS), the risk of viral infections reactivation is well known. This problem seems to be less evident in IMID patients who assume anti-tumour necrosis factor-α (anti-TNF-α) or other biologic therapies, although reactivations of Varicella-Zoster virus (VZV) and John Cunningham virus (JC) have been widely reported. As for CMV reactivation, very few data are available in patients with IMID undergoing biological treatment. Before starting biological therapy the screening for CMV infection is not recommended in the evidence-based consensus by the European Crohn's and Colitis Organization (1), by the European League Against Rheumatism (EULAR) (2) and by the Italian Society for Rheumatology (3). The aim of this work is to update the literature evidence on the risk of CMV reactivation in IMID patients, in order to understand if screening before biologic therapy is necessary.
n MATERIALS AND METHODS
A review of Pubmed and indexed literature on CMV and IMID was carried out. The following search terms were used in PubMed (http://www.ncbi.nlm.nih.gov/ pubmed/): Cytomegalovirus, anti-TNF, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel diseases. We included case report or case series until April 2015. In the other case reports, the antiviral treatment and the discontinuation of the immunosuppressive agents were associated with clinical improvement (6-9). The role of CMV in the exacerbations of IBD remains a topic of ongoing debate. CMV colitis is rare in patients with Crohn's disease or mild to moderate ulcerative colitis, but CMV reactivation can be detected in about 30% of patients with severe and/or steroidrefractory ulcerative colitis, with remission rates of 67-100% following antiviral therapy with intravenous ganciclovir. However, despite an inconclusive knowledge, testing for CMV reactivation should be performed in presence of refractory colitis and, in case of a positive result, antiviral therapy should be started (10). 
ORIGINAL PAPER
Referring to the rheumatic diseases patients, the French RATIO registry reported one case with rash and fever due to CMV in RA (primary infection or reactivation?) (4). In other reported cases (11-15), the discontinuation of immunomodulating therapy led to the improvement of the patients' conditions, with or without concomitant antiviral therapy. Haerter et al. (11) described a case of retinitis in a patient with RA with an impaired cellular immune state, probably due to treatment with cyclophosphamide and azathioprine. We found one report describing two CMV infections in patients affected by psoriasis during anti-TNF-α therapy (12) . In case of the novel therapies for RA, like Janus Kinase (JAK) inhibitors (tofacitinib), an analysis to determine the rate of infections reported 6 cases of CMV infection, but it's not clear if the clinical presentation was severe neither if it was a primary infection or a reactivation (13) . In Table I , we summarize the cases of CMV infection reported during biological therapy in IMID patients.
n DISCUSSION AND CONCLUSIONS
Our brief literature review is consistent with the hypothesis that, during anti-TNF-α therapy in IMID patients, CMV reactivation is possible, although the risk is very low. The clinical reports did not describe clearly if infection was primary or a reactivation. As a result, we cannot recommend anti-CMV antibodies detection or CMV-DNA testing in the infectious diseases screening applied to patients before starting biological treatment. This recommendation is also supported by the fact that the pre-emptive therapy would be generally not indicated, with the exception of some groups of immunocompromised patients (hematopoietic stem cell transplantation or acquired immunodeficiency syndrome).
On the other hand, it is important to underline that, in patients receiving biological drugs, presenting fever of unknown origin, particularly if associated with rash, hepatitis or visual field defects, clinicians should be aware of the risk of CMV reactivation and specific diagnostic tools should be performed.
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